Fineline Cube

Follow:
14437 Articles
Policy / Regulatory

Beijing Medical Insurance Bureau Announces Key Healthcare Initiatives and BMI Expansion

CompanyDrug

Joincare Pharmaceutical Receives NMPA Approval for Triptorelin Microspheres for Prostate Cancer

CompanyDrug

Zai Lab’s Repotrectinib on Track for Priority Review by China’s CDE for ROS1+ NSCLC

CompanyDrug

Sichuan Kelun Pharmaceutical’s A166 Anti-HER2 ADC NDA Accepted for Review by NMPA

CompanyDeals

Suzhou Porton Biologics and Synbio Technologies Partner to Advance Cell and Gene Therapy in China

CompanyDrug

Mabwell Bioscience’s 9MW3911 Receives NMPA Approval for Clinical Trial in Advanced Tumors

CompanyDrug

Akeso Biopharma Initiates Phase III Study for Ivonescimab in Non-Small Cell Lung Cancer

CompanyDrug

Zai Lab Limited Reports Q1 2023 Financial Results and Product Highlights

CompanyDrug

Yifan Pharmaceutical’s F-627 Receives NMPA Approval for Neutropenia Treatment in Cancer Patients

CompanyDrug

Jiangsu Nhwa Pharmaceutical Receives NMPA Approval for Olinvyk (Oliceridine) Injection

CompanyDrug

Innovent Biologics’ Tyvyt Secures NMPA Approval for EGFR-Mutated NSCLC Treatment

Policy / Regulatory

China’s NHC Releases Draft Guidelines for Somatic Cell Clinical Research, Seeks Public Input